The Incretin Space
A collection of collated data on incretin drug developments, including new drugs, new treatments and the future of incretin in medicine
Part 3 of the GIP series, cardiac benefits of GIP and a deep dive of the remarkable SURPASS CVOT trial results
Less nausea, more insulin sensitivity, and a little less inflammation Part 2 in a series on GIP
The master incretin of the alpha and beta cell starts to shinePart 1 in a series on GIP
Lilly's oral non-peptide GLP-1 could change everything & bimagrumab flexes its muscle, but at what cost?
More novel molecules, more side effects
Novo's Dual Amylin-GLP1 agonist shows promise but caveats apply
The next revolution in medicine arrives in 2026
(Ant)agonizing over glucose, and the next medical revolution
